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Abstract: Recent advances in high-throughput sequencing technology have identified the 
transcription of a much larger portion of the genome than previously anticipated. Especially in 
the context of cancer it has become clear that aberrant transcription of both protein-coding and 
long non-coding RNAs (lncRNAs) are frequent events. The current dogma of RNA function 
describes mRNA to be responsible for the synthesis of proteins, whereas non-coding RNA can 
have regulatory or epigenetic functions. However, this distinction between protein coding and 
regulatory ability of transcripts may not be that strict. Here, we review the increasing body  
of evidence for the existence of multifunctional RNAs that have both protein-coding and  
trans-regulatory roles. Moreover, we demonstrate that coding transcripts bind to components 
of the Polycomb Repressor Complex 2 (PRC2) with similar affinities as non-coding transcripts, 
revealing potential epigenetic regulation by mRNAs. We hypothesize that studies on the 
regulatory ability of disease-associated mRNAs will form an important new field of research. 
Keywords: non-coding RNA; epigenetic; mRNA; polycomb; remodeling; multifunctional; 
regulatory; transcript; lncRNA; lincRNA 
 
1. Introduction 
RNA molecules are best known for their ability to convey genetic information encoded in the DNA 
into the synthesis of specific proteins. This messenger function makes RNA an essential player in 
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today’s DNA/RNA/protein world. It is commonly believed that our current DNA/RNA/protein world 
was preceded by a so-called RNA-world, a term first used by Gilbert in 1986 [1]. This world was based 
primarily on RNA molecules, which stored genetic information similar to DNA, and catalyzed chemical 
reactions similar to enzyme proteins in today’s world [2,3]. The RNA-world hypothesis has implicated 
a crucial role for RNA in the origin of life. Also in today’s DNA-based life, the function of RNA 
molecules is not limited to being a messenger for protein synthesis. In fact, only about 1–2% of the 
RNA present within a human cell is protein-coding, the remainder being non-coding RNA (ncRNA). 
The vast majority of this ncRNA is ribosomal RNA (rRNA) and transfer RNA (tRNA)—both involved 
in the process of translation [4]—as well as mitochondrial RNA (mtRNA) transcribed from DNA 
present in the mitochondria. In addition, and especially thanks to recent advances in massive parallel 
sequencing, the near entire repertoire of RNA molecules has now been identified. Important work by 
the ENCODE Consortium on the characterization of the complete RNA profile of human cells has 
shown that about 62% of genomic bases is represented in RNA molecules [5]. To date, this has resulted 
in the annotation of 13,249 unique long non-coding RNAs (lncRNAs) versus the 20,447 known 
protein-coding loci (GENCODE v15) with lncRNA numbers likely to increase further in later releases 
of GENCODE [6]. From an ever-increasing number of functional studies it has become apparent that 
lncRNAs—transcripts over 200 nucleotides in size—are involved in the regulation of gene expression 
at many levels, ranging from changing the epigenetic state of genes to influencing mRNA stability and 
translation. Also in the context of cancer, many lncRNAs have been shown to possess tumor 
suppressive or oncogenic properties [7–17]. This implies there is a much more complex role for RNA 
in cancer than previously anticipated. This review highlights both the differences and similarities 
between protein-coding and long non-coding transcripts. The roles of short RNA molecules (such as 
miRNAs) and their involvement in cancer are excellently reviewed elsewhere (e.g., [18–22]). 
Importantly, we summarize evidence for multifunctional roles for protein-coding transcripts. These 
multifunctional roles warrant a further (re-)investigation of deregulated transcripts in cancer, at the 
protein level and at the regulatory level. 
2. Non-Coding versus Coding RNA 
For most mRNAs ample evidence for their protein coding ability exists. Likewise, an ever-growing 
list of publications proves the involvement of lncRNAs in diverse aspects of gene regulation. Despite 
this major discrepancy in function, lncRNAs are in many ways very similar to mRNAs. The majority 
of active lncRNA genes are occupied by the same histone modifications as protein-coding genes, are 
synthesized by the same RNA polymerase II transcriptional machinery, 5' capped and are often spliced 
with similar exon/intron lengths [23,24]. Moreover, most long non-coding transcripts are 
polyadenylated [25–27]. Alternatively, some lncRNAs are generated via alternative pathways, and are 
for example not polyadenylated and likely to be expressed by RNA polymerase III [25,28], or excised 
during splicing [29]. Still, most known lncRNAs and their biogenesis pathways are indistinguishable 
from mRNAs. Global analyses of long non-coding transcripts did reveal a general bias towards a  
two-exon structure and localization in the chromatin and nucleus [30]. They are also expressed at 
lower levels and more frequently in a cell type specific manner compared to mRNAs [31]. Still, there 
is a significant overlap between transcript expression levels and distribution of coding and non-coding 
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RNA. Only, their lack of protein coding ability and conservation is differentiating lncRNAs from 
mRNAs [26,32]. These are therefore the main criteria from telling both types of transcripts apart. 
Protein-coding ability—Proof of protein-coding ability can be obtained from experiments such as 
Western blotting using specific antibodies or via mass spectrometry. For example, in 2012, about  
one-third of all annotated human protein-coding genes were supported by peptide hits derived from 
mass spectrometry spectra submitted to PeptideAtlas [6]. This still leaves a large gap of evidence for 
many supposedly translated mRNAs. In contrast, finding proof of the inability of non-coding RNA to 
be translated into proteins is much harder. Bánfai and colleagues have shown that many annotated 
lncRNAs that are expressed at levels similar to mRNAs indeed lack mass spectrometry evidence, but 
still some did reveal peptides indicating they may be wrongly annotated as non-coding [33]. 
Theoretically, each open reading frame (ORF) containing a start and stop codon can give rise to a 
polypeptide or protein. To discriminate protein-coding from non-coding transcripts a minimum length 
of the ORF is generally being used. For example, the FANTOM consortium that analyzed the mouse 
transcriptome described coding RNA to have an ORF of at least 300 nucleotides (nt; i.e., 100 amino 
acids) [34]. Similarly, the human transcriptome was analyzed by another consortium called  
H-Invitational that used a cutoff of 60 nt (20 amino acids) [35]. Unfortunately, these arbitrary cutoffs 
are far from ideal and have resulted in numerous incorrectly annotated RNAs for several reasons. 
Firstly, ncRNAs are likely to have an ORF by chance [36]. For example, a group of well documented 
lncRNAs including H19, Xist, Mirg, Gtl2, and Kcnq1ot1 all contain ORFs longer than 100 codons, 
while they do not code for protein [37]. Secondly, transcripts with an experimentally proven ability to 
encode for proteins shorter than 100 amino acids, will be falsely considered as non-coding. Many of 
such known short proteins are involved in critical pathways in immunity, cell signaling and 
metabolism [38]. In fact, about five percent of all currently annotated proteins are less than 100 amino 
acids in size, which would all be incorrectly annotated using this cutoff (Figure 1). Lowering the 
threshold below 100 amino acids would allow the inclusion of very small known human proteins such 
as sarcolipin (SLN) [39] or ribosomal protein L41 (RPL41) with protein sizes of 31 and 25 amino acids, 
respectively [40]. Noncanonical, yet functional ORFs down to 11 amino acids have now been reported, 
indicating the possible existence of a new class of mRNAs [41]. However, setting the border of the 
ORF at a very low number of amino acids would obviously misclassify many ncRNA as coding RNA. 
Sequence conservation—Instead of measuring the length of the ORF one could also examine the 
evolutionary conservation of the ORF. If the ORF of a novel transcript shows homology with other 
known proteins this indicates that the RNA could function as mRNA, while novel, non-conserved 
ORFs are likely to occur by chance and often do not function as protein-coding [42]. However, more 
recent research has revealed a frequent lack of conservation in newly identified protein-coding  
exons [43]. A further complicating factor is the common evolution of protein-coding genes, or copies 
thereof, into ncRNAs, such as pseudogenes. For example, the Xist gene evolved from a protein-coding 
gene and therefore still shows great overlap with mRNA features and a strong conservation [44]. Other 
pseudogenes have even been shown to be resurrected into protein-coding genes, further complicating 
the feature discrimination between mRNAs and lncRNAs [45]. 
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Figure 1. Size distribution of human proteins. Out of all annotated proteins derived from 
the protein-coding gene list in the GENCODE database (version 15, August 2012 freeze, 
GRCh37—Ensembl 70), five percent are less than 100 amino acids in size (1,039 out of 
20,640). In this analysis, only the largest protein size was included when multiple isoforms 
were listed for a single gene ID. 
 
LncRNAs versus untranslated regions of mRNAs—Interestingly, a recent study revealed significant 
similarities between lncRNAs and the 3' untranslated regions (3' UTRs) in protein-coding RNAs in 
structural features and sequence composition [46]. Both lncRNAs and 3' UTRs obviously lack  
protein-coding capacity and are intron-poor. Importantly, also the secondary structure predictions were 
highly similar between lncRNAs and the 3' UTRs of protein-coding transcripts, most likely due to a 
similar (lower) GC content. Also thermodynamically, lncRNAs were more similar to UTRs than to 
coding sequences [47]. Moreover, direct sequence comparisons revealed highly similar hexamer 
compositions in lncRNAs and 3' UTRs, which differed significantly from 5' UTRs or ORFs [46].  
In conclusion, although lncRNAs and mRNAs do differ in their protein-coding ability, the  
above-mentioned facts about lncRNAs reveal a high degree of similarity between lncRNAs and 
mRNAs, or parts thereof. LncRNAs have been shown to play critical regulatory roles in diverse 
cellular processes including chromatin remodeling, transcription, post-transcriptional processing, as 
well as intracellular trafficking [48–50]. The presence of the intriguing parallels between the lncRNAs 
and mRNA raises the question whether protein coding transcripts may be able to fulfill regulatory 
functions similar to lncRNAs. 
3. Regulatory Functions of lncRNAs and mRNAs 
LncRNAs appear to be involved in nearly all aspects of gene regulation, including X-inactivation, 
imprinting, epigenetic regulation, nuclear and cytoplasmic trafficking, transcription, mRNA splicing 
and translation [51]. Through these involvements, lncRNAs have shown to be important players in a 
wide range of biological processes, such as proliferation, cell cycle, apoptosis, differentiation and 
maintenance of pluripotency [52]. Participation of lncRNAs into this wide range of processes can be 
explained by the ability of transcripts to fold into stable secondary structures, which in many cases 
dictate their functions [51]. Based on known examples, several functions have been proposed for 
lncRNAs. At the simplest level, lncRNAs can serve as decoys, preventing the access of transcription 
factors and other proteins to the chromatin [53,54]. In a scaffold model, lncRNAs can bring together 
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multiple protein partners to form ribonucleoprotein complexes. Importantly, the concept of RNA as 
molecular scaffold is likely to be a more common mode of action as hundreds of lncRNAs have been 
identified to form ribonucleic protein interactions with multiple protein partners [15,55–57]. Finally, 
lncRNAs can function as guides for the proper localization of specific regulatory protein complexes in 
cis (on neighboring genes) or in trans (distantly located genes). The protein complexes brought on by 
the lncRNAs can act as epigenetic repressors and activators, as well as transcription factors [58]. 
Knowledge on how lncRNAs search for selective sites in the genome and how they interact with 
chromatin or target RNAs is slowly accumulating. LncRNAs can interact with RNA molecules via the 
formation of complementary hybrids [8,59,60]. They can also directly bind DNA by forming stable 
triplex structures via base-pairing [53,61] or by displacing one of the DNA strands and forming  
so-called R loops [62]. Alternatively, sequence-specific DNA-binding proteins can guide lncRNAs to 
target regions in the genome [63]. Recently, a novel mechanism of lncRNA targeting via chromosomal 
looping has been described for HOTTIP lncRNA [64]. 
For more detailed information about the mechanisms of lncRNAs action we refer to excellent 
reviews by others [65–68]. Also, their involvement in gene deregulation in cancer has been thoroughly 
reviewed elsewhere [9,10,69]. However, such regulatory roles are not solely attributed to non-coding 
transcripts. Also protein-coding transcripts have been shown to be involved in a number of regulatory 
mechanisms. Of course, many examples of cis-regulatory functions of mRNAs are known—mostly 
residing in the non-coding regulatory elements (untranslated regions, or UTRs)—and involve the 
regulation of stability, splicing and translation of the transcript [70–72]. Regulatory elements in the  
5' UTR can play an important role in the control of translation initiation. Length, GC-content and 
secondary structures all affect translation efficiency [73,74]. Likewise, the 3' UTR can contain 
elements that are important in transcript cleavage, stability, translation and mRNA localization. The  
3' UTR serves as a binding site for numerous regulatory proteins as well as miRNAs [75–78]. 
Importantly, mRNAs can also affect other genes or gene products via trans-regulatory functions. 
Below, we describe known and putative trans-regulatory functions of mRNAs and compare them to 
known lncRNAs with similar functions. Each example is also mentioned in Table 1. 
Table 1. Regulatory functions of lncRNAs and mRNA and their type of interactions. 
Function 
Interaction 
lncRNA^ mRNA Mechanism References 
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structural 
 
 
  
    •   SATIII   
forms nuclear stress bodies by attracting splicing and transcription factors to 
SATIII repeats 
[79] 
    •   NEAT1   forms paraspeckles as large foci directly after transcription [80] 
    •     H2B forms HLBs and Cajal bodies [81] 
    •     VegT integral part of cytoskeleton at vegetal side in X. laevis oocytes [82] 
transcriptional 
control 
 
  
   
    •   MEG3   enhances p53 binding to promoters [83] 
    •   MALAT1   interacts with splicing factors to influence the localization and action [84] 
    •   GAS5   decoy for the glucocorticoid receptor [54] 
    •   DHFR-minor   prevents DHFR transcription via triple helix formation and TFIIB interaction [53] 
    •     SRA co-activator for many nuclear receptors and transcription factors [85–94] 
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Table 1. Cont. 
Function 
Interaction 
lncRNA^ mRNA Mechanism References 
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transcription 
elongation 
    • 
 
7SK   binds and inhibits P-TEFb, thereby blocking RNAPII elongation [95–99] 
    • 
 
  HIC 
binds and activates P-TEFb by displacing 7SK RNA from inhibitory 
complex, allowing RNAPII elongation 
[100] 
miRNA sponge 
  
  
  
  •     PTEN-P1   binds miRNAs that also target PTEN, thereby increasing PTEN protein levels [101] 
  •     HULC   binds amongst others miR-372, thereby increasing PRKACB protein levels [102] 
  •       VCAN 
binds miR-133a, miR-199a*, miR-144 and miR-431, thereby increasing 
protein levels of CD34 and FN1 
[103] 
  •       CD44 
binds miR-328, miR-512-3p, miR-491 and miR671, thereby increasing 
protein levels of COL1α1 and FN1  
[104] 
RNA 
degradation 
 
•       1/2sbsRNAs   
imperfect base-pairing with Alu elements in UTRs of mRNA, thereby 
attraction STAU1 and initializing STAU1-mediated decay 
[60] 
•         speculative 
imperfect base-pairing between Alu elements in two mRNAs, thereby 
attraction STAU1 and initializing STAU1-mediated decay 
[105] 
translational 
control 
  
  
  
  
  
  
  
•   •   lincRNA-p21   
imperfect base-pairing with mRNA can directly impair translation and/or can 
attract translation inhibitors 
[8] 
•       
PU.1-
antisense 
  processed RNA binds sense PU.1 transcript and stalls translation [106] 
•         BCMA-AS blocks translation of the sense BCMA transcript [107] 
    •   BC1   
interacts with eIF4A and PABP and blocks their interaction, thereby 
repressing the general translation machinery 
[108] 
    •     
cytoskeletal 
mRNAs 
inhibit translation by interaction with the RNA-binding domain of PKR, 
resulting in PKR phosphorylation events 
[109] 
     •     P23/TCTP 
inhibit translation by interaction with the RNA-binding domain of PKR, 
resulting in PKR phosphorylation events 
[110] 
    •     
VEGFA, 
TPM1, 
IFN-γ, 
TNF-α 
UTR interacts with PKR, thereby inhibiting translation [111–114] 
    •     p53 
interacts with MDM2, thereby preventing p53 degradation and promoting 
p53 translation 
[115] 
unknown  
  
      • PCAT1   trans-regulates many genes, including BRCA2 [116] 
      •   PHB 3' UTR has unknown trans-regulatory role [117] 
      •   RNR 3' UTR has unknown trans-regulatory role [118] 
      •   c-myc P0 5' UTR has unknown trans-regulatory role [119] 
guide for 
epigenetic 
enzymes 
  
  
  
  
   
    •   HOTTIP   interacts with WDR5/MLL complex [64] 
    •   HOTAIR   interacts with PRC2 and LSD1-CoREST complex [55] 
    •   ANRIL   interacts with PRC1 and PRC2 complexes [15,57] 
        HOTAIRM1   interacts with PRC1 and PRC2 complexes [120] 
    •   KCNQ1OT1   interacts with PRC2 complexes and G9a [56] 
    •   AIR   interacts with G9a [121] 
    •   pRNA   recruits DNMT3b to rDNA promoters [61] 
    •     many § many mRNAs interact with PRC2 complex components § 
^: listed lncRNAs serve as examples for each functional group; §: Reanalysis of our data [unpublished], Guil et al. data [29] and Zhao et al. 
data [122] revealed many mRNAs, see also Section 4. 
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3.1. Structural Function 
LncRNAs can serve as structural scaffolds involved in the formation of nuclear domains. The first 
described non-coding RNA with a structural role is Satellite III (SATIII) [79]. SATIII is involved in the 
formation of nuclear stress bodies (nSBs) when cells are subjected to thermal, hypertonic or chemical 
stresses [123]. These cellular stresses change the heterochromatin state of SATIII repeats on 
chromosome 9q11-12 to a euchromatin state. After transcription, SATIII RNA remains within the locus 
and recruits serine-arginine rich splicing factor SF2/ASF and several heat shock transcription factors 
like HSF1 and SAF-B to form nSBs [124]. SATIII was even shown to be sufficient for the formation of 
nSBs in the absence of a stress trigger [81]. A second lncRNA with an architectural role within the 
nucleus is nuclear-enriched autosomal transcript (NEAT1). NEAT1 is a 3.7 kb long unspliced, 
polyadenylated transcript that is localized at the edges of SC35 domains in paraspeckles, which are 
found in all cells in interphase [125,126]. NEAT1 was concluded to be essential for the assembly, 
maintenance and structural integrity of these paraspeckles [80,126,127]. 
Not only ncRNAs, but also mRNAs have been shown to perform architectural roles for cellular 
substructures. Two of these nuclear structures are the histone locus bodies (HLBs) and the associated 
Cajal bodies. The HLBs are known to harbor large amounts of histone pre-mRNA and histone 3'-end 
processing components [128], whereas the Cajal bodies contain small nuclear ribonucleoproteins 
(snRNPs) and are suggested to generate and recycle these proteins [129,130]. The de novo formation 
of both these nuclear components was shown to be induced by histone 2b (H2B) pre-mRNA [81]. In 
the same paper, spliced RNA Polymerase II transcripts are suggested to contribute to the 
morphogenesis of splicing speckles by functioning as a scaffold for pre-mRNA splicing factors. 
Another good example of an mRNA with a structural role is VegT, found in Xenopus laevis  
oocytes [131]. The VegT transcript was shown to be an integral part of the cytokeratin cytoskeleton at 
the vegetal cortex of the oocytes and responsible for the localization of Vg1, Bicaudal-C and Wnt11 
mRNAs at this position. Depletion of VegT mRNA therefore resulted in the delocalization of these 
mRNAs [131]. Furthermore, the acquired disruption in the cytokeratin cytoskeleton network could be 
rescued by injecting exogenous VegT mRNA [82]. 
3.2. Transcriptional Control 
A second level of lncRNA-directed regulation is by (co-)transcriptional control. Here, the 
recruitment of RNA polymerase II, transcription factors and/or co-factors to gene promoters is 
facilitated or prevented by long non-coding RNAs. The lncRNA MEG3 activates the p53 tumor 
suppressor gene and the growth differentiation factor 15 (GDF15) gene by enhancing p53 binding to 
the GDF15 gene promoter, thereby inhibiting cell proliferation [83]. While MEG3 is expressed in 
many normal human tissues, reduced levels of MEG3 are frequently observed in a variety of cancers 
and associated with hyper-proliferation [14,132,133]. Another example is the abundant lncRNA 
MALAT1, which is frequently upregulated in many cancers and can regulate alternative splicing by 
modulating the phosphorylation of serine/arginine-rich splicing factors (SRSFs) [12,134–136]. 
Depletion of MALAT1 altered the localization and activity of these splicing factors, leading to altered 
splicing patterns for a set of pre-mRNAs [84]. The lncRNA GAS5 contains a hairpin sequence motif, 
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mimicking a DNA binding site of the glucocorticoid receptor, thereby serving as a decoy to release the 
receptor from the DNA and preventing transcription of metabolic genes [54]. In the case of the human 
dihydrofolate reductase (DHFR) gene, a lncRNA initiated from the upstream DHFR-minor promoter 
inhibits the assembly of the pre-initiation complex at the major promoter by forming a stable triple 
helix complex with promoter sequences, as well as through direct interactions with the general 
transcription factor IIB (TFIIB) resulting in the silencing of the DHFR gene [53,66]. 
The human Steroid Receptor RNA Activator (SRA) transcript was initially identified as a ncRNA 
that co-activates the Progesterone Receptor [86]. More recently, SRA RNA has been confirmed to  
co-activate many nuclear receptors, including estrogen (α and β), androgen, glucocorticoid, retinoic acid 
(α), peroxisome proliferator activated receptors (δ and γ), thyroid and vitamin D receptors [87–89,137], 
reviewed in [85]. Additionally, it was shown that SRA RNA can enhance the activity of transcription 
factors like MyoD and GATA3 [90,91]. It is thought that SRA ncRNA functions as a scaffold for 
nucleoprotein complexes with both positive regulators (e.g., receptor co-activator SRC-1, RNA 
helicases p68 and p72, pseudo-uridine synthases Pus1p and Pus3p [86,88,90,92,93,138]) and negative 
regulators (such as the SMRT/HDAC1 Associated Repressor Protein SHARP or the SRA stem-loop 
interacting RNA-binding protein SLIRP [89,94,139]). With the discovery of three new isoforms of 
SRA it was shown that these could also be translated into the protein SRAP [140]. Considering the fact 
that these longer SRA isoforms include the same core sequence as needed for the regulatory RNA 
function, this RNA was concluded to be bi-functional. Deregulated SRA RNA levels have been 
implicated in a variety of cancers [141–146]. Interestingly, high expression levels of the SRAP protein 
were shown to be a predictor for positive outcome in breast cancer [147].  
3.3. Transcription Elongation 
Transcriptional pausing is a well-known phenomenon, where RNA polymerase II (RNAPII) 
becomes trapped downstream of the transcriptional start site (TSS) and is unable to escape into 
productive elongation [148]. P-TEFb, the positive transcription elongation factor, plays an essential 
role in facilitating RNAPII escape from this paused state. When recruited to promoters, P-TEFb 
phosphorylates the C-terminal domain (CTD) of RNAPII, allowing the escape into productive 
elongation [148]. In vivo, P-TEFb is present in two states: an active P-TEFb form, associated with 
Brd4 and other factors, and in an inactive ribonucleoprotein form, referred to as 7SK snRNP, 
containing a 331-nt non-coding RNA known as 7SK snRNA. RNase footprinting and mutagenesis 
experiments have indicated that 7SK contains a high degree of secondary structure, with stem-loops at 
both the 5' and 3' ends [96,148–150]. The 5' stem loop binds P-TEFb as well as the Hexim1 protein, 
which acts to inhibit the kinase activity, while the 3' stem-loop binds the Larp7/PIP7S protein, which, 
in addition to a methylphosphate capping enzyme (Mepce), stabilizes the RNA [95–99,151,152]. For a 
long time the mechanism of P-TEFb release from the inhibitory complex was not known. However, a 
recent study has demonstrated the important role of HIC mRNA for P-TEFb activation [100]. The 3' UTR 
of HIC mRNA binds to and activates P-TEFb by displacing 7SK RNA from inhibitory complex. 
Analysis of the secondary structure of HIC mRNA 3' terminal region revealed the existence of hairpins 
resembling similar structures within 7SK RNA [100]. It is speculated that other mRNAs with similar 
secondary structure may exert the same function and multiple P-TEFbs containing RNPs exist [100].  
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3.4. miRNA Sponge 
MicroRNAs—a large class of small ncRNAs—have emerged as a critical element in gene regulation 
by interacting with incompletely complementary sequences in target messenger RNAs [66,153,154]. 
They function by annealing to complementary sites on the coding sequences or 3' UTRs of target gene 
transcripts, where they promote the recruitment of protein complexes that impair translation and/or 
decrease the stability of mRNA, ultimately leading to a decreased target protein abundance [153,154]. 
Aberrant expression of miRNAs has been linked to many cancer types as well as other human  
diseases [155,156]. There is now evidence that the inverse mechanism may also take place, whereby 
mRNA levels can affect the distribution of miRNAs. Such RNA molecules can compete for miRNA 
binding, thereby acting as a miRNA sponge or decoy independent of a possible protein-coding 
function (reviewed in [157]). Natural miRNA sponges were first discovered in plants [158] and more 
recently also in virally infected primate cells [159], and in human cells [101]. The miRNA sponge/decoy 
function has been recently described for a number of lncRNAs. Specifically, the 3' region of the 
PTEN-P1 lncRNA was found to bind the same set of regulatory miRNA sequences that normally target 
the tumor-suppressor gene PTEN, alleviating the PTEN mRNA repression and allowing its translation 
into the tumor-suppressor protein PTEN [66,101]. Another interesting example is lncRNA HULC, which 
may act as an endogenous miRNA sponge that down-regulates a series of miRNAs, including  
miR-372. Inhibition of miR-372 by HULC led to reduced translational repression of its target gene, 
PRKACB, which in turn induced phosphorylation of transcription factor CREB [102,160]. 
Similarly, two mRNA transcripts were recently shown to act as miRNA sponges: the 3' UTR 
regions of Versican (VCAN) mRNA in hepatocellular carcinoma (HCC) and of CD44 mRNA in breast 
cancer cells [103,104]. The elevated levels of VCAN mRNA in HCC and HepG2 cells sequester  
miR-133a, miR-199a*, miR-144 and miR-431, thereby increasing the protein levels of amongst others 
CD34 and fibronectin (FN1), which have similar miRNA binding sites in their 3' UTRs [103]. 
Increased levels of the 3' UTR of VCAN increased proliferation, survival, migration, invasion, colony 
formation, and enhanced endothelial cell growth, but decreased apoptosis [103]. Similarly, CD44 
mRNA is elevated in breast cancer cells and its 3' UTR harbors binding sites for miR-328, miR-512-3p, 
miR-491 and miR671 [104]. Elevated CD44 (3' UTR) levels sequester these miRNAs thereby 
increasing the protein levels of amongst others COL1α1 and fibronectin 1 (FN1), and enhanced the cell 
motility, invasion and cell adhesion and metastasis. Figure 2 shows a schematic representation of the 
miRNA sponge function of mRNA molecules. Importantly, by binding these miRNAs, the UTR 
sequences not only regulate their own transcript level homeostasis, they may also affect other 
transcripts by changing the available pool of these miRNAs through their decoy function [161]. 
Dynamics in this mode of regulation can be obtained by changing the length of the 3' UTR. For 
example, rapidly proliferating cells express shortened 3' UTRs, thereby decreasing the available 
positions for miRNA to bind [162]. 
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Figure 2. miRNA sponge function for mRNA. In a normal cell, a specific miRNA can 
target a number of mRNAs resulting in the inhibition of translation and/or degradation of 
these transcripts. When the expression levels of one of the mRNAs targeted by this miRNA 
is changed, a redistribution of the specific miRNA will cause a change in protein translation 
for multiple transcripts. In this schematic figure, the overexpressed yellow mRNA 
functions as a sponge for the red miRNA, yielding increased green and blue protein levels. 
In contrast, a depletion of the yellow miRNA sponge would result in a decrease in green, 
blue and yellow protein levels. 
 
3.5. RNA Degradation 
Global transcriptome analyses has provided evidence that a large proportion of the genome can 
simultaneously produce transcripts from both strands, and that antisense transcripts commonly link 
―neighboring genes‖ in complex loci into chains of linked transcriptional units [163]. According to 
data generated by the FANTOM3 project, 4,520 pairs of full-length transcripts were able to form 
sense/antisense pairs on exons as detected in the mouse genome. Among them, 1,687 pairs were 
formed between protein coding genes, 2,478 by protein-coding/non-coding gene pairs and 355 by  
non-coding genes only [163]. Expression profiling revealed frequent concordant regulation of these 
sense/antisense pairs. One of the possible mechanisms for this transcript-mediated gene regulation is 
based on the sense-antisense RNA duplex formation. These sense-antisense transcript pairs can be 
regarded as Natural Antisense Transcripts (NATs). NATs are simply RNAs containing sequences that 
are complementary to other endogenous RNAs [105]. These can occur in cis, as described above,  
but they can also be transcribed in trans from separate loci (trans-NATs). Both cis- and trans-NATs 
can affect gene expression at the level of transcription, maturation, transport, stability and  
translation [105]. Numerous examples of cis- and trans-acting lncRNAs base-pairing with mRNA 
molecules and affecting its stability or translation have been describe so far [8,59,106,164–166]. 
A recently discovered group of trans-acting lncRNAs, termed half-STAU1-binding site RNAs 
(½-sbsRNAs), can activate the decay of specific target mRNAs. Staufen 1 (STAU1)-mediated 
messenger RNA decay (SMD) involves the degradation of translationally active mRNAs upon STAU1 
binding to the 3' UTR via double-stranded RNA [60]. STAU1-binding sites are formed by imperfect 
base-pairing between an Alu element in the 3' UTR of an mRNA target and an Alu element in a 
cytoplasmic lncRNA [60]. Evidently, Alu elements are highly needed to form RNA duplexes between 
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mRNA and lncRNA that can be recognized by STAU1. As many mRNAs contain Alu elements in 
their 3' UTRs, it is highly plausible that also direct mRNA-mRNA base pairing may be a substrate for 
STAU1-mediated decay. A bioinformatic analysis revealed many stretches of imperfect base-pairing 
between Alu sequences localized within 5' and 3' UTR regions of mRNAs, similar to the ½-sbsRNAs 
mode of action [105]. Whether such putative mRNA-mRNA pairings are functional and act via the 
SMD pathway will be the topic of future research. 
3.6. Translational Control 
LncRNAs are best known for their roles as regulators of transcription. However, recent studies have 
shown an important role of long non-coding RNAs in mRNA translation [8,106,108,164]. LncRNAs 
can modulate translation by two different mechanisms. As mentioned above, the cis- and trans-acting 
lncRNAs are capable to pair with mRNA molecules forming double-stranded RNA structures and thus 
inhibiting mRNA translation [8,106]. Alternatively, lncRNAs can act by affecting the general 
translation machinery [108]. LincRNA-p21 is an example of a trans-acting lncRNA involved in 
translation inhibition [8,167]. The transcripts CTNNB1 and JUNB (encoding β-catenin and JunB, 
respectively) base-pair imperfectly with lincRNA-p21 at several places throughout the coding regions 
and UTRs. The formed lincRNA-p21-mRNA complex further interacts with translation repressors Rck 
and Fmrp, suggesting that lincRNA-p21 can repress the translation of target mRNAs by operating via 
multiple mechanisms [8,167]. Another example of a cis-acting lncRNAs is antisense mRNA for PU.1 
gene [106,168]. The processed antisense RNA in the cytoplasm can bind to the sense PU.1 transcript 
and stall translation between initiation and elongation steps [106,168].  
Protein-coding antisense mRNA transcripts are also capable to form RNA duplexes with sense 
mRNA molecules leading to translation inhibition. Antisense BCMA RNA is transcribed from the same 
locus as BCMA and has typical mRNA features, e.g., polyadenylation, splicing, Kozak consensus 
sequence and an open reading frame encoding an experimentally proven 115 amino acid peptide:  
p12 protein [107]. Experimental data suggests that antisense BCMA inhibits the expression of BCMA 
protein, while it does not affect the expression level of BCMA mRNA. The inhibition of BCMA 
expression is obtained through the action of the antisense RNA and not of the p12 protein, although the 
exact mechanism is not fully understood [107].  
A ncRNA that acts by affecting the general translation machinery is the Xenopus laevis transcript 
BC1. BC1 transcript—expressed in neurons and germ cells—inhibits the assembly of the translation 
initiation complex [169]. The 3' region of the BC1 RNA interacts with eIF4A and PABP and disrupts 
the functional link between the two factors which is necessary for efficient translation in Xenopus 
oocytes [108]. A near-complete restoration of translation occurs after introduction of excess eIF4A and 
PABP, indicating that translation repression by BC1 happens via eIF4A and PABP [108]. 
The ability to inhibit the general translation machinery is also identified for several mRNAs. These 
transcripts mainly act through the interaction of their UTRs with the RNA-dependent protein kinase 
(PKR). PKR is a serine-threonine protein kinase that is activated by intermolecular autophosphorylation 
upon binding to RNA molecules. The 3' UTR regions of cytoskeletal muscle mRNAs can act as  
trans-regulators by inhibiting translation through the activation of PKR [109]. Specifically, the  
3' UTRs of tropomyosin, troponin and cardiac actin mRNAs can induce muscle cell differentiation and 
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appear to function as tumor suppressors. These RNA sequences are predicted to form secondary 
structures with extended duplex stretches. It was shown that the 3' UTRs of cytoskeletal mRNAs 
interact with the RNA-binding domain of the PKR [109]. Once activated, PKR phosphorylates its 
substrates, including translation initiation factor eIF2α, which results in sequestration of another 
initiation factor, eIF2β, ultimately leading to inhibition of protein synthesis [109]. An important 
observation from this study is that full-length mRNA transcripts are more efficient at inhibiting 
translation than only their 3' UTR regions, suggesting the entire transcript is required for proper 
functioning [109]. Similarly, the P23/TCTP full-length mRNA but not a truncated version thereof, was 
able to bind and activate PKR, resulting in the inhibition of translation [110]. Several other protein 
coding transcripts have been reported to interact with PKR through their structured UTRs: the 5' UTRs 
of VEGFA mRNA [111] and IFN-γ mRNA [112], and the 3′ UTRs of TPM1 mRNA [113] and TNF-α 
mRNA [114]. In all cases PKR activation caused inhibition of translation, which can have a cis effect 
on the translation level of the mRNA itself as well as a more general trans effect on the translation 
level of other transcripts. 
Another mRNA with translational control is the tumor suppressor gene p53 [115]. This gene is 
mutated in about half of all cancers and therefore considered a driver mutation gene [170,171]. The 
p53 protein works mainly as a transcription factor that acts upon cellular stresses such as DNA 
damage, stress of the endoplasmic reticulum (ER), hypoxia and telomere erosion [172]. When p53 is 
induced by this cellular stress, it can trans-activate a variety of target genes which promote cell cycle 
arrest, senescence or apoptosis [173,174]. Another p53 target with a different function is the MDM2 
gene. Its protein product is an E3 ubiquitin ligase which promotes polyubiquitination and proteasomal 
degradation of p53, thereby forming a negative regulatory feedback loop [175–177]. Interestingly, 
MDM2 is also involved in a positive regulatory feedback loop of p53. The mRNA of p53 can interact 
with the RING domain of MDM2, which prevents the E3 ligase activity and furthermore stimulates 
translation of the p53 mRNA [115]. At first, the interaction between the MDM2 protein and p53 
mRNA was considered to control the function of MDM2 [115]. Later, it was demonstrated that 
phosphorylation of the Ser395 residue of MDM2 is required for the p53 mRNA-MDM2 interaction 
and thereby acts as the switch for MDM2 between being a negative or a positive regulator [178]. 
3.7. Unknown Function 
Recently, an example of a regulatory lncRNA in prostate cancer was described, with a proven 
functionality, but through a yet unknown mechanism of action [116]. In this high throughput  
RNA-sequencing study on clinical prostate cancer samples, a panel of 121 transcriptionally deregulated 
lncRNAs (Prostate Cancer-Associated Transcripts, or PCATs) were identified, representing potentially 
functional lncRNAs associated with prostate cancer. One of these transcripts, called PCAT-1 was 
selectively upregulated only in prostate cancer and shown to function predominantly as a transcriptional 
repressor by facilitating trans-regulation of genes preferentially involved in mitosis and cell division, 
including known tumor suppressor genes, such as BRCA2 [116]. 
Also several mRNAs, and more specifically their UTRs, have been reported to function as 
regulators (riboregulators) that suppress tumor formation but through unknown mechanisms. Results 
from Rastinejad and Blau suggest that the 3' UTRs of certain differentiation-specific RNAs are  
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trans-acting regulators in feedback loops that inhibit cell division and promote differentiation [179]. 
More recently, the 3' UTR of several other transcripts were shown to reduce proliferation and induce 
differentiation of both myogenic cells and fibroblasts. The 3' UTR of prohibitin (PHB), an inhibitor of 
cell proliferation, significantly suppresses the tumorigenic properties and metastatic phenotype of 
transformed MCF7 cells [117]. Similarly, the 3' UTR of ribonucleotide reductase (RNR), a key  
rate-limiting enzyme in DNA synthesis, significantly suppresses the tumorigenic properties and 
metastatic phenotype of transformed fibroblasts cells [118]. Also the 5' UTR can fulfill such actions: 
the 5' UTR of the human c-myc P0 transcript suppresses the malignant phenotype of human breast 
cancer cells with decreased anchorage-independent proliferation, enhanced susceptibility to programmed 
cell death, and complete loss of the ability to form tumors in the intact animal [119]. For all these cases 
mentioned above, it is clear the UTRs harbor trans-regulatory functions, but the exact mechanism of 
their action is currently still unknown.  
4. Epigenetic Regulatory Potential of Protein-Coding RNA  
It is well known that many lncRNAs are involved in the regulation of gene expression at the 
epigenetic level. Approximately 20–30% of all lncRNAs have been shown to be able to physically 
interact with specific epigenetic enzymes, which control the reversible modification of histone residues 
and DNA methylation, thereby influencing the activity of genes [120,180]. Upon binding, the 
lncRNAs can guide chromatin modifying complexes to their target regions. Such lncRNAs can guide 
either gene activators (for example the lncRNAs HOTTIP [64] or Mistral [181]) or gene repressors 
(e.g., HOTAIR [55], HOTAIRM1 [120], ANRIL [15,57], Kcnq1ot1 [56], Air [121], Xist [182] or  
pRNA [61]). LncRNAs can even function as a scaffold, bringing together multiple protein partners to 
form ribonucleoprotein complexes, which are subsequently guided to their genomic target locations. 
For example, HOTAIR can simultaneously bind to both the polycomb repressive complex 2 (PRC2) 
and the LSD1-CoREST complex using specific domains of the RNA molecule [55], while ANRIL and 
HOTAIRM1 directly interact with proteins from both PRC1 and PRC2 complexes [15,57,120]. 
Similarly, the lncRNA Kcnq1ot1 interacts with both the PRC2 and G9a (EHMT2) to lay down the 
silencing histone marks H3K27me3 and H3K9me2, respectively [56]. In recent attempts to characterize 
all RNA molecules that interact with the PRC2 complex, RNA immunoprecipitation experiments 
combined with next generation sequencing have been conducted by us and others [29,122,183]. Thus 
far, these studies have mainly focused on the interactions between lncRNAs and PRC2 complex 
components. Zhao and colleagues focused mainly on imprinted non-coding transcripts and MEG3 in 
particular, which directs PRC2 to the reciprocally imprinted Dlk1 coding gene [122]. Guil et al. only 
describe results for non-coding intronic RNA sequences [29]. They report several intronic RNA 
regions capable of interacting with PRC2 components and inducing repression of the host gene in cis. 
One of their examples is the SMYD3 intronic RNA, which can bind to EZH2, a component of the 
PRC2 complex, thereby targeting this repressive complex to the SMYD3 gene. SMYD3 is a SET 
domain-containing H3K4 methyltransferase with oncogenic properties, which is frequently 
overexpressed in colorectal, breast and liver cancer [184,185]. Reducing the levels of SMYD3 by 
SMYD3 intronic RNA, resulted in reduced tumor growth, and revealed SMYD3 intronic RNA to harbor 
tumor suppressive abilities [29]. Similarly, several other intronic RNAs with stand-alone regulatory 
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functions were recently described in mice, implicating this to be a common type of multi-functionality 
within mammalian (primary) transcripts [186]. Finally, in experiments from our own laboratory, we 
analyzed the binding ability of transcripts over 200 nucleotides in size to SUZ12, one of the PRC2 
complex components, in prostate cancer cells [183]. Both SUZ12 and EZH2 proteins are part of  
the PRC2 complex, contain RNA binding domains and have been shown to interact with RNA  
molecules [55,57,182,187]. 
To specifically gain insight into the binding of protein-coding RNA molecules to the PRC2 
complex, we initially compared results for both mRNAs and lncRNAs in experiments from our own 
laboratory. In these experiments, we determined the SUZ12-bound RNA fraction in the human prostate 
cancer cell line LNCaP upon formaldehyde-fixation (RNA-IP) via next-generation sequencing and 
compared these results to input material [183]. To our surprise, protein-coding transcripts appeared to 
bind to the PRC2 complex with similar affinities as lncRNAs did. In fact, a substantial portion of 
mRNAs (and lncRNAs) bound with even stronger affinities to PRC2 than previously reported 
lncRNA-PRC2 interactors, including HOTAIRM1, ANRIL and KCNQ1OT1 (Figure 3A). Independent 
replicates reproduced our initial findings. Next, we decided to reanalyze the raw data from similar 
experiments from the Esteller laboratory [29]. In these experiments EZH2-RNA interactions were 
studied in the human colorectal cancer cell line HCT116 by UV cross-linking (iCLIP) and next-generation 
sequencing. We compared the levels of EZH2-bound transcripts with background levels (IgG-bound 
fraction) to calculate fold-enrichment values. This reanalysis confirmed the findings from our own 
experimental data, and showed similar enrichment levels for mRNAs and lncRNAs, again with many 
transcripts binding stronger than known lncRNA interactors (Figure 3B). The (re-)analysis of data 
from both the Esteller lab and our lab yielded very similar results, even though both studies were 
conducted in different cancer cell lines, targeting different PRC2 complex components and using 
different experimental set ups. Finally, we included results from the Zhao et al. study, in which mouse 
embryonic stem cells were used to identify RNAs that interacted with the PRC2 complex component 
EZH2 via immunoprecipitation and next-generation sequencing [122]. There, over 9,000 transcripts 
were detected that interacted with EZH2, including many protein-coding genes (Table 2). Even though 
the depth of sequencing in this study was much lower than the study by Guil et al. and our study, their 
data also showed frequent enrichments of protein-coding transcripts, in particular those encoding for 
oncogenes and tumor suppressors, similar to transcripts from imprinted genes. 
Table 2. EZH2-binding transcripts in mouse ES cells. Table is adapted from Zhao and 
colleagues [122]. 
Gene type % enriched # enriched # total examined 
lncRNAs 10.2% 216 2,127 
Oncogenes 44.3% 182 411 
Tumor Suppresor Genes 41.0% 325 793 
Imprinted Genes 41.0% 34 83 
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Figure 3. RNA binding to PRC2 complex components. (A) Analysis of data from our lab 
showed that both mRNAs and lncRNAs bind to the PRC2 complex component SUZ12 
with similar binding affinities [183]. For comparison, known lncRNA-PRC2 interactions 
and their fold enrichments are shown in red. Here, the RNA-IP experiments were performed 
on the prostate cancer cell line LNCaP upon formaldehyde-fixation; (B) Reanalysis of the 
raw data from the Guil et al. confirmed our finding that both protein-coding and non-coding 
RNA can bind with high affinity to the PRC2 complex, in this case the EZH2 subunit [29]. 
These data were obtained from UV cross-linking experiments (iCLIP) in the colorectal 
cancer cell line HCT116. 
 
In conclusion, all three studies described above imply a vast level of interaction between proteins of 
the PRC2 complex and protein-coding RNAs. These results are also in line with recent  
mRNA-proteome interaction studies where mRNAs appear to interact with regulatory enzymes and 
proteins. In these large proteome studies hundreds of mRNA binding proteins were identified [188,189]. 
As expected, the list of RNA binders was enriched for already known RNA binding proteins, involved 
in mRNA splicing, localization, processing and translation. However, also proteins functioning in 
transcription regulation were clearly identified, including transcription factors and co-activators (such 
as MYBBP1A and EDF) [188]. What functions these RNA-protein interactions have and by what 
mechanism these proteins may modulate transcription remains to be determined. Here, we hypothesize 
that mRNAs such as those binding to the PRC2 complex can indeed have additional regulatory 
functions (Figure 4). Currently, we cannot rule out the possibility that these mRNA-PRC2 interactions 
are non-specific events, but their levels of enrichment in all three studies are similar to or even stronger 
than known functional lncRNA-PRC2 interactions. Further studies are needed to prove a functional 
role for these mRNA-PRC2 interactions. 
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Figure 4. Proposed guide function for mRNA. Many mRNAs have here been shown to 
interact with PRC2 complex components. Similar to lncRNAs, we propose that mRNAs 
are involved in guiding the PRC2 complex to its target locations in the genome, where it 
can repress genomic regions by depositing a trimethyl mark on the lysine 27 residue of 
histone H3 (K27me3). Which part of the mRNA directly interacts with the PRC2 complex 
is currently not known. 
 
5. Conclusions 
From the vast amount of papers it is clear that long non-coding RNA can have a variety of 
important roles in gene deregulation in cancer. Evidence of similar roles for protein-coding transcripts 
is now slowly accumulating. Here, we have combined, reviewed and extended the current knowledge 
of trans-regulatory roles for mRNA. Side-by-side, we have compared lncRNA and mRNA examples 
with similar regulatory functions. We have shown that mRNAs can frequently be associated with the 
PRC2 complex components and hypothesize a common guiding role for mRNA molecules. Future 
experiments need to further substantiate these speculations. Lastly, conclusions from loss-of-function 
experiments for mRNAs may need to be reinterpreted as the effects may not automatically be solely 
attributed to the associated protein function, but instead may also be partially due to affected 
regulatory functions. Again, further experimentation will show the extent of these regulatory roles for 
coding RNA. 
Acknowledgments 
This work was supported by a grant from the E.U. (PIRG5-GA-2009-248397) and fellowships to 
M.W.C. from the Nijmegen Centre for Molecular Life Sciences, and the Netherlands Organisation for 
Scientific Research (NWO: Veni ZonMW: 916.10.108). 
References  
1. Gilbert, W. Origin of life—The RNA world. Nature 1986, 319, 618–618. 
2. Joyce, G.F. The antiquity of RNA-based evolution. Nature 2002, 418, 214–221. 
Cancers 2013, 5 478 
 
 
3. Orgel, L.E. Prebiotic chemistry and the origin of the RNA world. Crit. Rev. Biochem. Mol. Biol. 
2004, 39, 99–123. 
4. Berg, J.M.; Tymoczko, J.L.; Stryer, L. Biochemistry; Freeman: New York, NY, USA, 2003. 
5. The_ENCODE_Project_Consortium. An integrated encyclopedia of DNA elements in the human 
genome. Nature 2012, 489, 57–74. 
6. Harrow, J.; Frankish, A.; Gonzalez, J.M.; Tapanari, E.; Diekhans, M.; Kokocinski, F.;  
Aken, B.L.; Barrell, D.; Zadissa, A.; Searle, S.; et al. Gencode: The reference human genome 
annotation for the encode project. Genome Res. 2012, 22, 1760–1774. 
7. Huarte, M.; Guttman, M.; Feldser, D.; Garber, M.; Koziol, M.J.; Kenzelmann-Broz, D.;  
Khalil, A.M.; Zuk, O.; Amit, I.; Rabani, M.; et al. A large intergenic noncoding RNA induced by 
p53 mediates global gene repression in the p53 response. Cell 2010, 142, 409–419. 
8. Yoon, J.H.; Abdelmohsen, K.; Srikantan, S.; Yang, X.L.; Martindale, J.L.; De, S.; Huarte, M.; 
Zhan, M.; Becker, K.G.; Gorospe, M. Lincrna-p21 suppresses target mRNA translation.  
Mol. Cell 2012, 47, 648–655. 
9. Huarte, M.; Rinn, J.L. Large non-coding RNAs: Missing links in cancer? Hum. Mol. Genet. 
2010, 19, R152–R161. 
10. Gutschner, T.; Diederichs, S. The hallmarks of cancer a long non-coding RNA point of view.  
RNA Biol. 2012, 9, 703–719. 
11. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; 
Argani, P.; Rinn, J.L.; et al. Long non-coding RNA hotair reprograms chromatin state to promote 
cancer metastasis. Nature 2010, 464, 1071–1076. 
12. Ji, P.; Diederichs, S.; Wang, W.; Boing, S.; Metzger, R.; Schneider, P.M.; Tidow, N.; Brandt, B.; 
Buerger, H.; Bulk, E.; et al. Malat-1, a novel noncoding RNA, and thymosin beta4 predict metastasis 
and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22, 8031–8041. 
13. Mourtada-Maarabouni, M.; Pickard, M.R.; Hedge, V.L.; Farzaneh, F.; Williams, G.T. Gas5, a 
non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 
2009, 28, 195–208. 
14. Zhang, X.; Gejman, R.; Mahta, A.; Zhong, Y.; Rice, K.A.; Zhou, Y.; Cheunsuchon, P.;  
Louis, D.N.; Klibanski, A. Maternally expressed gene 3, an imprinted noncoding RNA gene, is 
associated with meningioma pathogenesis and progression. Cancer Res. 2010, 70, 2350–2358. 
15. Yap, K.L.; Li, S.D.; Munoz-Cabello, A.M.; Raguz, S.; Zeng, L.; Mujtaba, S.; Gil, J.; Walsh, M.J.; 
Zhou, M.M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 
27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 2010, 38, 662–674. 
16. Yu, W.Q.; Gius, D.; Onyango, P.; Muldoon-Jacobs, K.; Karp, J.; Feinberg, A.P.; Cui, H.M. 
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451,  
202–206. 
17. Gibb, E.A.; Vucic, E.A.; Enfield, K.S.; Stewart, G.L.; Lonergan, K.M.; Kennett, J.Y.;  
Becker-Santos, D.D.; MacAulay, C.E.; Lam, S.; Brown, C.J.; et al. Human cancer long  
non-coding rna transcriptomes. PLoS One 2011, 6, e25915. 
18. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6,  
857–866. 
Cancers 2013, 5 479 
 
 
19. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. 
Cancer 2006, 6, 259–269. 
20. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 
2009, 10, 704–714. 
21. Esteller, M. Non-coding rnas in human disease. Nat. Rev. Genet. 2011, 12, 861–874. 
22. Mattick, J.S.; Makunin, I.V. Small regulatory rnas in mammals. Hum. Mol. Genet. 2005, 14, 
R121–R132. 
23. Guttman, M.; Amit, I.; Garber, M.; French, C.; Lin, M.F.; Feldser, D.; Huarte, M.; Zuk, O.; 
Carey, B.W.; Cassady, J.P.; et al. Chromatin signature reveals over a thousand highly conserved 
large non-coding RNAs in mammals. Nature 2009, 458, 223–227. 
24. Derrien, T.; Johnson, R.; Bussotti, G.; Tanzer, A.; Djebali, S.; Tilgner, H.; Guernec, G.; Martin, D.; 
Merkel, A.; Knowles, D.G.; et al. The gencode v7 catalog of human long noncoding RNAs: 
Analysis of their gene structure, evolution, and expression. Genome Res. 2012, 22, 1775–1789. 
25. Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; 
Hertel, J.; Hackermuller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a 
possible function for pervasive transcription. Science 2007, 316, 1484–1488. 
26. Dinger, M.E.; Pang, K.C.; Mercer, T.R.; Mattick, J.S. Differentiating protein-coding and 
noncoding RNA: Challenges and ambiguities. PLoS Comput. Biol. 2008, 4, e1000176. 
27. Sana, J.; Faltejskova, P.; Svoboda, M.; Slaby, O. Novel classes of non-coding RNAs and cancer.  
J. Transl. Med. 2012, doi:10.1186/1479-5876-10-103. 
28. Dieci, G.; Fiorino, G.; Castelnuovo, M.; Teichmann, M.; Pagano, A. The expanding RNA 
polymerase III transcriptome. Trends Genet. 2007, 23, 614–622. 
29. Guil, S.; Soler, M.; Portela, A.; Carrere, J.; Fonalleras, E.; Gomez, A.; Villanueva, A.;  
Esteller, M. Intronic RNAs mediate EZH2 regulation of epigenetic targets. Nat. Struct. Mol. Biol. 
2012, 19, 664–670. 
30. Furuno, M.; Pang, K.C.; Ninomiya, N.; Fukuda, S.; Frith, M.C.; Bult, C.; Kai, C.; Kawai, J.; 
Carninci, P.; Hayashizaki, Y.; et al. Clusters of internally primed transcripts reveal novel long 
noncoding RNAs. PLoS Genet. 2006, 2, 537–553. 
31. Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; 
Lagarde, J.; Lin, W.; Schlesinger, F.; et al. Landscape of transcription in human cells. Nature 
2012, 489, 101–108. 
32. Lin, M.F.; Jungreis, I.; Kellis, M. PhyloCSF: A comparative genomics method to distinguish 
protein coding and non-coding regions. Bioinformatics 2011, 27, i275–i282. 
33. Bánfai, B.; Jia, H.; Khatun, J.; Wood, E.; Risk, B.; Gundling, W.E.; Kundaje, A.; Gunawardena, 
H.P.; Yu, Y.; Xie, L.; et al. Long noncoding RNAs are rarely translated in two human cell lines. 
Genome Res. 2012, 22, 1646–1657. 
34. Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; 
Saito, R.; Suzuki, H.; et al. Analysis of the mouse transcriptome based on functional annotation 
of 60,770 full-length cDNAs. Nature 2002, 420, 563–573. 
35. Imanishi, T.; Itoh, T.; Suzuki, Y.; O'Donovan, C.; Fukuchi, S.; Koyanagi, K.O.; Barrero, R.A.; 
Tamura, T.; Yamaguchi-Kabata, Y.; Tanino, M.; et al. Integrative annotation of 21,037 human 
genes validated by full-length cDNA clones. PLoS Biol. 2004, 2, 856–875. 
Cancers 2013, 5 480 
 
 
36. Dinger, M.E.; Gascoigne, D.K.; Mattick, J.S. The evolution of RNAs with multiple functions. 
Biochimie 2011, 93, 2013–2018. 
37. Prasanth, K.V.; Spector, D.L. Eukaryotic regulatory RNAs: An answer to the ―genome 
complexity‖ conundrum. Genes Dev. 2007, 21, 11–42. 
38. Frith, M.C.; Forrest, A.R.; Nourbakhsh, E.; Pang, K.C.; Kai, C.; Kawai, J.; Carninci, P.; 
Hayashizaki, Y.; Bailey, T.L.; Grimmond, S.M. The abundance of short proteins in the 
mammalian proteome. PLoS Genet. 2006, 2, 515–528. 
39. Odermatt, A.; Taschner, P.E.; Scherer, S.W.; Beatty, B.; Khanna, V.K.; Cornblath, D.R.; 
Chaudhry, V.; Yee, W.C.; Schrank, B.; Karpati, G.; et al. Characterization of the gene encoding 
human sarcolipin (SLN), a proteolipid associated with serca1: Absence of structural mutations in 
five patients with brody disease. Genomics 1997, 45, 541–553. 
40. Klaudiny, J.; von der Kammer, H.; Scheit, K.H. Characterization by cdna cloning of the mRNA 
of a highly basic human protein homologous to the yeast ribosomal protein yl41. Biochem. 
Biophys. Res. Commun. 1992, 187, 901–906. 
41. Galindo, M.I.; Pueyo, J.I.; Fouix, S.; Bishop, S.A.; Couso, J.P. Peptides encoded by short ORFs 
control development and define a new eukaryotic gene family. PLoS Biol. 2007, 5, 1052–1062. 
42. Clamp, M.; Fry, B.; Kamal, M.; Xie, X.H.; Cuff, J.; Lin, M.F.; Kellis, M.; Lindblad-Toh, K.; 
Lander, E.S. Distinguishing protein-coding and noncoding genes in the human genome.  
Proc. Natl. Acad. Sci. USA 2007, 104, 19428–19433. 
43. Lindblad-Toh, K.; Garber, M.; Zuk, O.; Lin, M.F.; Parker, B.J.; Washietl, S.; Kheradpour, P.; 
Ernst, J.; Jordan, G.; Mauceli, E.; et al. A high-resolution map of human evolutionary constraint 
using 29 mammals. Nature 2011, 478, 476–482. 
44. Duret, L.; Chureau, C.; Samain, S.; Weissenbach, J.; Avner, P. The xist RNA gene evolved in 
eutherians by pseudogenization of a protein-coding gene. Science 2006, 312, 1653–1655. 
45. Brosch, M.; Saunders, G.I.; Frankish, A.; Collins, M.O.; Yu, L.; Wright, J.; Verstraten, R.; 
Adams, D.J.; Harrow, J.; Choudhary, J.S.; et al. Shotgun proteomics aids discovery of novel 
protein-coding genes, alternative splicing, and ―resurrected‖ pseudogenes in the mouse genome. 
Genome Res. 2011, 21, 756–767. 
46. Niazi, F.; Valadkhan, S. Computational analysis of functional long noncoding rnas reveals lack 
of peptide-coding capacity and parallels with 3' UTRs. RNA 2012, 18, 825–843. 
47. Wan, Y.; Qu, K.; Ouyang, Z.; Kertesz, M.; Li, J.; Tibshirani, R.; Makino, D.L.; Nutter, R.C.; 
Segal, E.; Chang, H.Y. Genome-wide measurement of RNA folding energies. Mol. Cell 2012, 
48, 169–181. 
48. Hannon, G.J.; Rivas, F.V.; Murchison, E.P.; Steitz, J.A. The expanding universe of noncoding 
RNAs. Cold Spring Harb. Symp. Quant. Biol. 2006, 71, 551–564. 
49. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions.  
Nat. Rev. Genet. 2009, 10, 155–159. 
50. Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and functions of long noncoding rnas. Cell 2009, 
136, 629–641. 
51. Mercer, T.R.; Mattick, J.S. Structure and function of long noncoding RNAs in epigenetic 
regulation. Nat. Struct. Mol. Biol. 2013, 20, 300–307. 
Cancers 2013, 5 481 
 
 
52. Qiu, M.T.; Hu, J.W.; Yin, R.; Xu, L. Long noncoding RNA: An emerging paradigm of cancer 
research. Tumour Biol. 2013, doi:10.1007/s13277-013-0658-6. 
53. Martianov, I.; Ramadass, A.; Serra Barros, A.; Chow, N.; Akoulitchev, A. Repression of the 
human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 2007, 445, 
666–670. 
54. Kino, T.; Hurt, D.E.; Ichijo, T.; Nader, N.; Chrousos, G.P. Noncoding RNA gas5 is a growth 
arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal. 2010, 3, ra8. 
55. Tsai, M.C.; Manor, O.; Wan, Y.; Mosammaparast, N.; Wang, J.K.; Lan, F.; Shi, Y.; Segal, E.; 
Chang, H.Y. Long noncoding RNA as modular scaffold of histone modification complexes. 
Science 2010, 329, 689–693. 
56. Pandey, R.R.; Mondal, T.; Mohammad, F.; Enroth, S.; Redrup, L.; Komorowski, J.; Nagano, T.; 
Mancini-Dinardo, D.; Kanduri, C. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific 
transcriptional silencing through chromatin-level regulation. Mol. Cell 2008, 32, 232–246. 
57. Kotake, Y.; Nakagawa, T.; Kitagawa, K.; Suzuki, S.; Liu, N.; Kitagawa, M.; Xiong, Y. Long 
non-coding RNA anril is required for the PRC2 recruitment to and silencing of p15(INK4B) 
tumor suppressor gene. Oncogene 2011, 30, 1956–1962. 
58. Guttman, M.; Rinn, J.L. Modular regulatory principles of large non-coding RNAs. Nature 2012, 
482, 339–346. 
59. Faghihi, M.A.; Modarresi, F.; Khalil, A.M.; Wood, D.E.; Sahagan, B.G.; Morgan, T.E.;  
Finch, C.E.; St. Laurent, G., 3rd; Kenny, P.J.; Wahlestedt, C. Expression of a noncoding RNA is 
elevated in alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase.  
Nat. Med. 2008, 14, 723–730. 
60. Gong, C.; Maquat, L.E. LncRNAs transactivate STAU1-mediated mrna decay by duplexing with  
3' UTRs via Alu elements. Nature 2011, 470, 284–288. 
61. Schmitz, K.M.; Mayer, C.; Postepska, A.; Grummt, I. Interaction of noncoding RNA with the 
rDNA promoter mediates recruitment of DNMT3B and silencing of rRNA genes. Genes Dev. 
2010, 24, 2264–2269. 
62. Aguilera, A.; Garcia-Muse, T. R loops: From transcription byproducts to threats to genome 
stability. Mol. Cell 2012, 46, 115–124. 
63. Jeon, Y.; Lee, J.T. YY1 tethers Xist RNA to the inactive X nucleation center. Cell 2011, 146,  
119–133. 
64. Wang, K.C.; Yang, Y.W.; Liu, B.; Sanyal, A.; Corces-Zimmerman, R.; Chen, Y.; Lajoie, B.R.; 
Protacio, A.; Flynn, R.A.; Gupta, R.A.; et al. A long noncoding RNA maintains active chromatin 
to coordinate homeotic gene expression. Nature 2011, 472, 120–124. 
65. Rinn, J.L.; Chang, H.Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 
2012, 81, 145–166. 
66. Wang, K.C.; Chang, H.Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 2011, 43, 
904–914. 
67. Baldassarre, A.; Masotti, A. Long non-coding RNAs and p53 regulation. Int. J. Mol. Sci. 2012, 
13, 16708–16717. 
68. Da Sacco, L.; Baldassarre, A.; Masotti, A. Bioinformatics tools and novel challenges in long 
non-coding RNAs (lncRNAs) functional analysis. Int. J. Mol. Sci. 2012, 13, 97–114. 
Cancers 2013, 5 482 
 
 
69. Chen, G.; Wang, Z.; Wang, D.; Qiu, C.; Liu, M.; Chen, X.; Zhang, Q.; Yan, G.; Cui, Q. 
Lncrnadisease: A database for long-non-coding Rna-associated diseases. Nucleic Acids Res. 
2013, 41, D983–D986. 
70. Chen, J.Z.; Yang, T.; Yu, H.; Sun, K.; Shi, Y.; Song, W.H.; Bai, Y.Y.; Wang, X.J.; Lou, K.J.; 
Song, Y.; et al. A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by 
interfering with the binding efficiency of microRNA 211. Hum. Mol. Genet. 2010, 19, 2524–2533. 
71. Delay, C.; Calon, F.; Mathews, P.; Hebert, S.S. Alzheimer-specific variants in the 3' UTR of 
amyloid precursor protein affect microrna function. Mol. Neurodegener. 2011, 6, 
doi:10.1186/1750-1326-6-70. 
72. Wilkie, G.S.; Dickson, K.S.; Gray, N.K. Regulation of mrna translation by 5'- and 3'-UTR-
binding factors. Trends Biochem. Sci. 2003, 28, 182–188. 
73. Kochetov, A.V.; Ischenko, I.V.; Vorobiev, D.G.; Kel, A.E.; Babenko, V.N.; Kisselev, L.L.; 
Kolchanov, N.A. Eukaryotic mrnas encoding abundant and scarce proteins are statistically 
dissimilar in many structural features. FEBS Lett. 1998, 440, 351–355. 
74. Pickering, B.M.; Willis, A.E. The implications of structured 5' untranslated regions on translation 
and disease. Semin. Cell Dev. Biol. 2005, 16, 39–47. 
75. Eulalio, A.; Huntzinger, E.; Izaurralde, E. Getting to the root of miRNA-mediated gene silencing. 
Cell 2008, 132, 9–14. 
76. Lee, I.; Ajay, S.S.; Yook, J.I.; Kim, H.S.; Hong, S.H.; Kim, N.H.; Dhanasekaran, S.M.; 
Chinnaiyan, A.M.; Athey, B.D. New class of microrna targets containing simultaneous 5'-UTR 
and 3'-UTR interaction sites. Genome Res. 2009, 19, 1175–1183. 
77. Lytle, J.R.; Yario, T.A.; Steitz, J.A. Target mRNAs are repressed as efficiently by microRNA-
binding sites in the 5' UTR as in the 3' UTR. Proc. Natl. Acad. Sci. USA 2007, 104, 9667–9672. 
78. Zhang, L.N.; Liu, Y.X.; Song, F.J.; Zheng, H.; Hu, L.M.; Lu, H.; Liu, P.F.; Hao, X.S.; Zhang, W.; 
Chen, K.X. Functional SNP in the microrna-367 binding site in the 3' UTR of the calcium 
channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc. 
Natl. Acad. Sci. USA 2011, 108, 13653–13658. 
79. Valgardsdottir, R.; Chiodi, F.; Giordano, M.; Cobianchi, F.; Riva, S.; Biamonti, G. Structural and 
functional characterization of noncoding repetitive RNAs transcribed in stressed human cells.  
Mol. Biol. Cell 2005, 16, 2597–2604. 
80. Clemson, C.M.; Hutchinson, J.N.; Sara, S.A.; Ensminger, A.W.; Fox, A.H.; Chess, A.;  
Lawrence, J.B. An architectural role for a nuclear noncoding RNA: Neat1 RNA is essential for 
the structure of paraspeckles. Mol. Cell 2009, 33, 717–726. 
81. Shevtsov, S.P.; Dundr, M. Nucleation of nuclear bodies by RNA. Nat. Cell Biol. 2011, 13,  
167–173. 
82. Kloc, M.; Wilk, K.; Vargas, D.; Shirato, Y.; Bilinski, S.; Etkin, L.D. Potential structural role of 
non-coding and coding RNAs in the organization of the cytoskeleton at the vegetal cortex of 
xenopus oocytes. Development 2005, 132, 3445–3457. 
83. Zhou, Y.; Zhong, Y.; Wang, Y.; Zhang, X.; Batista, D.L.; Gejman, R.; Ansell, P.J.; Zhao, J.; 
Weng, C.; Klibanski, A. Activation of p53 by MEG3 non-coding RNA. J. Biol. Chem. 2007, 
282, 24731–24742. 
Cancers 2013, 5 483 
 
 
84. Tripathi, V.; Ellis, J.D.; Shen, Z.; Song, D.Y.; Pan, Q.; Watt, A.T.; Freier, S.M.; Bennett, C.F.; 
Sharma, A.; Bubulya, P.A.; et al. The nuclear-retained noncoding RNA MALAT1 regulates 
alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 2010, 39,  
925–938. 
85. Colley, S.M.; Leedman, P.J. Sra and its binding partners: An expanding role for RNA-binding 
coregulators in nuclear receptor-mediated gene regulation. Crit. Rev. Biochem. Mol. Biol. 2009, 
44, 25–33. 
86. Lanz, R.B.; McKenna, N.J.; Onate, S.A.; Albrecht, U.; Wong, J.M.; Tsai, S.Y.; Tsai, M.J.; 
O’Malley, B.W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an 
SRC-1 complex. Cell 1999, 97, 17–27. 
87. Deblois, G.; Giguere, V. Ligand-independent coactivation of er alpha AF-1 by steroid receptor 
RNA activator (SRA) via MAPK activation. J. Steroid Biochem. Mol. Biol. 2003, 85, 123–131. 
88. Zhao, X.S.; Patton, J.R.; Davis, S.L.; Florence, B.; Ames, S.J.; Spanjaard, R.A. Regulation of 
nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of 
steroid receptor rna activator. Mol. Cell 2004, 15, 549–558. 
89. Hatchell, E.C.; Colley, S.M.; Beveridge, D.J.; Epis, M.R.; Stuart, L.M.; Giles, K.M.;  
Redfern, A.D.; Miles, L.E.C.; Barker, A.; MacDonald, L.M.; et al. SLIRP, a small SRA binding 
protein, is a nuclear receptor corepressor. Mol. Cell 2006, 22, 657–668. 
90. Caretti, G.; Schiltz, R.L.; Dilworth, F.J.; Di Padova, M.; Zhao, P.; Ogryzko, V.; Fuller-Pace, 
F.V.; Hoffman, E.P.; Tapscott, S.J.; Sartorelli, V. The RNA helicases p68/p72 and the noncoding 
RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev. Cell 2006, 11,  
547–560. 
91. Hube, F.; Velasco, G.; Rollin, J.; Furling, D.; Francastel, C. Steroid receptor rna activator protein 
binds to and counteracts SRA RNA-mediated activation of MyoD and muscle differentiation. 
Nucleic Acids Res. 2011, 39, 513–525. 
92. Watanabe, M.; Yanagisawa, J.; Kitagawa, H.; Takeyama, K.; Ogawa, S.; Arao, Y.; Suzawa, M.; 
Kobayashi, Y.; Yano, T.; Yoshikawa, H.; et al. A subfamily of RNA-binding DEAD-box 
proteins acts as an estrogen receptor ALPHA coactivator through the N-terminal activation 
domain (AF-1) with an RNA coactivator, SRA. EMBO J. 2001, 20, 1341–1352. 
93. Zhao, X.S.; Patton, J.R.; Ghosh, S.K.; Fischel-Ghodsian, N.; Shen, L.; Spanjaard, R.A.  
Pus3p-and Pus1p-dependent pseudouridylation of steroid receptor RNA activator controls a 
functional switch that regulates nuclear receptor signaling. Mol. Endocrinol. 2007, 21, 686–699. 
94. Lanz, R.B.; Razani, B.; Goldberg, A.D.; O'Malley, B.W. Distinct RNA motifs are important for 
coactivation of steroid hormone receptors by steroid receptor RNA activator (SRA). Proc. Natl. 
Acad. Sci. USA 2002, 99, 16081–16086. 
95. Yik, J.H.; Chen, R.; Nishimura, R.; Jennings, J.L.; Link, A.J.; Zhou, Q. Inhibition of P-TEFb 
(CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of 
HEXIM1 and 7SK snRNA. Mol. Cell 2003, 12, 971–982. 
96. Egloff, S.; van Herreweghe, E.; Kiss, T. Regulation of polymerase ii transcription by 7SK 
snRNA: Two distinct rna elements direct P-TEFb and HEXIM1 binding. Mol. Cell. Biol. 2006, 
26, 630–642. 
Cancers 2013, 5 484 
 
 
97. Nguyen, V.T.; Kiss, T.; Michels, A.A.; Bensaude, O. 7SK small nuclear rna binds to and inhibits 
the activity of CDK9/Cyclin T complexes. Nature 2001, 414, 322–325. 
98. Barboric, M.; Kohoutek, J.; Price, J.P.; Blazek, D.; Price, D.H.; Peterlin, B.M. Interplay between 
7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-Tefb.  
EMBO J. 2005, 24, 4291–4303. 
99. He, N.; Jahchan, N.S.; Hong, E.; Li, Q.; Bayfield, M.A.; Maraia, R.J.; Luo, K.; Zhou, Q.  
A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent 
transcriptional elongation and tumorigenesis. Mol. Cell 2008, 29, 588–599. 
100. Young, T.M.; Tsai, M.; Tian, B.; Mathews, M.B.; Pe’ery, T. Cellular mrna activates transcription 
elongation by displacing 7SK RNA. PLoS One 2007, 2, e1010. 
101. Poliseno, L.; Salmena, L.; Zhang, J.W.; Carver, B.; Haveman, W.J.; Pandolfi, P.P.  
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. 
Nature 2010, 465, 1033–1038. 
102. Wang, J.Y.; Liu, X.F.; Wu, H.C.; Ni, P.H.; Gu, Z.D.; Qiao, Y.X.; Chen, N.; Sun, F.Y.; Fan, Q.S. 
CREB up-regulates long non-coding RNA, HULC expression through interaction with 
microRNA-372 in liver cancer. Nucleic Acids Res. 2010, 38, 5366–5383. 
103. Fang, L.; Du, W.W.; Yang, X.; Chen, K.; Ghanekar, A.; Levy, G.; Yang, W.; Yee, A.J.;  
Lu, W.Y.; Xuan, J.W.; et al. Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in 
inducing the development of hepatocellular carcinoma by regulating mirna activity. FASEB J. 
2013, 27, 907–919. 
104. Rutnam, Z.J.; Yang, B.B. The non-coding 3' UTR of CD44 induces metastasis by regulating 
extracellular matrix functions. J. Cell Sci. 2012, 125, 2075–2085. 
105. Wang, P.; Yin, S.; Zhang, Z.; Xin, D.; Hu, L.; Kong, X.; Hurst, L.D. Evidence for common short 
natural trans sense-antisense pairing between transcripts from protein coding genes. Genome 
Biol. 2008, 9, R169. 
106. Ebralidze, A.K.; Guibal, F.C.; Steidl, U.; Zhang, P.; Lee, S.; Bartholdy, B.; Jorda, M.A.;  
Petkova, V.; Rosenbauer, F.; Huang, G.; et al. Pu.1 expression is modulated by the balance of 
functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev. 
2008, 22, 2085–2092. 
107. Hatzoglou, A.; Deshayes, F.; Madry, C.; Lapree, G.; Castanas, E.; Tsapis, A. Natural antisense 
RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. BMC Mol. 
Biol. 2002, 3, 4. 
108. Wang, H.; Iacoangeli, A.; Lin, D.; Williams, K.; Denman, R.B.; Hellen, C.U.; Tiedge, H. 
Dendritic BC1 RNA in translational control mechanisms. J. Cell Biol. 2005, 171, 811–821. 
109. Nussbaum, J.M.; Gunnery, S.; Mathews, M.B. The 3'-untranslated regions of cytoskeletal muscle 
mrnas inhibit translation by activating the double-stranded rna-dependent protein kinase PKR. 
Nucleic Acids Res. 2002, 30, 1205–1212. 
110. Bommer, U.A.; Borovjagin, A.V.; Greagg, M.A.; Jeffrey, I.W.; Russell, P.; Laing, K.G.; Lee, M.; 
Clemens, M.J. The mRNA of the translationally controlled tumor protein p23/TCTP is a highly 
structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA 2002, 8, 478–496. 
Cancers 2013, 5 485 
 
 
111. Masuda, K.; Teshima-Kondo, S.; Mukaijo, M.; Yamagishi, N.; Nishikawa, Y.; Nishida, K.; 
Kawai, T.; Rokutan, K. A novel tumor-promoting function residing in the 5' non-coding region 
of vascular endothelial growth factor mRNA. PLoS Med. 2008, 5, e94. 
112. Ben-Asouli, Y.; Banai, Y.; Pel-Or, Y.; Shir, A.; Kaempfer, R. Human interferon-gamma mrna 
autoregulates its translation through a pseudoknot that activates the interferon-inducible protein 
kinase PKR. Cell 2002, 108, 221–232. 
113. Davis, S.; Watson, J.C. In vitro activation of the interferon-induced, double-stranded  
RNA-dependent protein kinase PKR by RNA from the 3' untranslated regions of human  
alpha-tropomyosin. Proc. Natl. Acad. Sci. USA 1996, 93, 508–513. 
114. Osman, F.; Jarrous, N.; Ben-Asouli, Y.; Kaempfer, R. A cis-acting element in the 3'-untranslated 
region of human TNF-alpha mRNA renders splicing dependent on the activation of protein 
kinase PKR. Genes Dev. 1999, 13, 3280–3293. 
115. Candeias, M.M.; Malbert-Colas, L.; Powell, D.J.; Daskalogianni, C.; Maslon, M.M.; Naski, N.; 
Bourougaa, K.; Calvo, F.; Fahraeus, R. P53 mRNA controls p53 activity by managing Mdm2 
functions. Nat. Cell Biol. 2008, 10, 1098–1105. 
116. Prensner, J.R.; Iyer, M.K.; Balbin, O.A.; Dhanasekaran, S.M.; Cao, Q.; Brenner, J.C.; Laxman, B.; 
Asangani, I.A.; Grasso, C.S.; Kominsky, H.D.; et al. Transcriptome sequencing across a prostate 
cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.  
Nat. Biotechnol. 2011, 29, 742–749. 
117. Manjeshwar, S.; Branam, D.E.; Lerner, M.R.; Brackett, D.J.; Jupe, E.R. Tumor suppression by 
the prohibitin gene 3' untranslated region RNA in human breast cancer. Cancer Res. 2003, 63, 
5251–5256. 
118. Fan, H.; Villegas, C.; Huang, A.; Wright, J.A. Suppression of malignancy by the 3' untranslated 
regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res. 1996, 56, 4366–4369. 
119. Blume, S.W.; Miller, D.M.; Guarcello, V.; Shrestha, K.; Meng, Z.; Snyder, R.C.; Grizzle, W.E.; 
Ruppert, J.M.; Gartland, G.L.; Stockard, C.R.; et al. Inhibition of tumorigenicity by the  
5'-untranslated RNA of the human c-myc P0 transcript. Exp. Cell Res. 2003, 288, 131–142. 
120. Guttman, M.; Donaghey, J.; Carey, B.W.; Garber, M.; Grenier, J.K.; Munson, G.; Young, G.; 
Lucas, A.B.; Ach, R.; Bruhn, L.; et al. Lincrnas act in the circuitry controlling pluripotency and 
differentiation. Nature 2011, 477, 295–300. 
121. Nagano, T.; Mitchell, J.A.; Sanz, L.A.; Pauler, F.M.; Ferguson-Smith, A.C.; Feil, R.; Fraser, P. 
The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. 
Science 2008, 322, 1717–1720. 
122. Zhao, J.; Ohsumi, T.K.; Kung, J.T.; Ogawa, Y.; Grau, D.J.; Sarma, K.; Song, J.J.; Kingston, R.E.; 
Borowsky, M.; Lee, J.T. Genome-wide identification of polycomb-associated RNAs by  
RIP-seq. Mol. Cell 2010, 40, 939–953. 
123. Alastalo, T.P.; Hellesuo, M.; Sandqvist, A.; Hietakangas, V.; Kallio, M.; Sistonen, L. Formation 
of nuclear stress granules involves HSF2 and coincides with the nucleolar localization of Hsp70.  
J. Cell Sci. 2003, 116, 3557–3570. 
124. Biamonti, G.; Caceres, J.F. Cellular stress and RNA splicing. Trends Biochem. Sci. 2009, 34,  
146–153. 
Cancers 2013, 5 486 
 
 
125. Fox, A.H.; Lam, Y.W.; Leung, A.K.L.; Lyon, C.E.; Andersen, J.; Mann, M.; Lamond, A.I. 
Paraspeckles: A novel nuclear domain. Curr. Biol. 2002, 12, 13–25. 
126. Hutchinson, J.N.; Ensminger, A.W.; Clemson, C.M.; Lynch, C.R.; Lawrence, J.B.; Chess, A.  
A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 
splicing domains. BMC Genomics 2007, 8, 39. 
127. Sasaki, Y.T.F.; Ideue, T.; Sano, M.; Mituyama, T.; Hirose, T. Men epsilon/beta noncoding rnas 
are essential for structural integrity of nuclear paraspeckles. Proc. Natl. Acad. Sci. USA 2009, 
106, 2525–2530. 
128. Marzluff, W.F.; Wagner, E.J.; Duronio, R.J. Metabolism and regulation of canonical histone 
mRNAs: Life without a poly(a) tail. Nat. Rev. Genet. 2008, 9, 843–854. 
129. Cioce, M.; Lamond, A.I. Cajal bodies: A long history of discovery. In Annual Review of  
Cell and Developmental Biology; Annual Reviews: Palo Alto, CA, USA, 2005; Volume 21,  
pp. 105–131. 
130. Matera, A.G.; Izaguire-Sierra, M.; Praveen, K.; Rajendra, T.K. Nuclear bodies: Random 
aggregates of sticky proteins or crucibles of macromolecular assembly? Dev. Cell 2009, 17,  
639–647. 
131. Heasman, J.; Wessely, O.; Langland, R.; Craig, E.J.; Kessler, D.S. Vegetal localization of 
maternal mRNAs is disrupted by vegt depletion. Dev. Biol. 2001, 240, 377–386. 
132. Braconi, C.; Kogure, T.; Valeri, N.; Huang, N.; Nuovo, G.; Costinean, S.; Negrini, M.; Miotto, E.; 
Croce, C.M.; Patel, T. MicroRNA-29 can regulate expression of the long non-coding RNA gene 
MEG3 in hepatocellular cancer. Oncogene 2011, 30, 4750–4756. 
133. Benetatos, L.; Hatzimichael, E.; Dasoula, A.; Dranitsaris, G.; Tsiara, S.; Syrrou, M.; Georgiou, I.; 
Bourantas, K.L. CPG methylation analysis of the MEG3 and snRPN imprinted genes in acute 
myeloid leukemia and myelodysplastic syndromes. Leuk. Res. 2010, 34, 148–153. 
134. Yamada, K.; Kano, J.; Tsunoda, H.; Yoshikawa, H.; Okubo, C.; Ishiyama, T.; Noguchi, M. 
Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci. 2006, 97, 
106–112. 
135. Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T.S. A large noncoding RNA is a marker for 
murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007, 26, 
851–858. 
136. Tano, K.; Mizuno, R.; Okada, T.; Rakwal, R.; Shibato, J.; Masuo, Y.; Ijiri, K.; Akimitsu, N. 
Malat-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of 
motility-related genes. FEBS Lett. 2010, 584, 4575–4580. 
137. Kawashima, H.; Takano, H.; Sugita, S.; Takahara, Y.; Sugimura, K.; Nakatani, T. A novel steroid 
receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator 
gene: Expression in prostate cancer cells and enhancement of androgen receptor activity. 
Biochem. J. 2003, 369, 163–171. 
138. Charette, M.; Gray, M.W. Pseudouridine in RNA: What, where, how, and why. IUBMB Life 
2000, 49, 341–351. 
139. Shi, Y.H.; Downes, M.; Xie, W.; Kao, H.Y.; Ordentlich, P.; Tsai, C.C.; Hon, M.; Evans, R.M. 
Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev. 
2001, 15, 1140–1151. 
Cancers 2013, 5 487 
 
 
140. Emberley, E.; Huang, G.J.; Hamedani, M.K.; Czosnek, A.; Ali, D.; Grolla, A.; Lu, B.;  
Watson, P.H.; Murphy, L.C.; Leygue, E. Identification of new human coding steroid receptor 
RNA activator isoforms. Biochem. Biophys. Res. Commun. 2003, 301, 509–515. 
141. Hussein-Fikret, S.; Fuller, P.J. Expression of nuclear receptor coregulators in ovarian stromal and 
epithelial tumours. Mol. Cell. Endocrinol. 2005, 229, 149–160. 
142. Lanz, R.B.; Chua, S.S.; Barron, N.; Soder, B.M.; DeMayo, F.; O’Malley, B.W. Steroid receptor 
RNA activator stimulates proliferation as well as apoptosis in vivo. Mol. Cell. Biol. 2003, 23, 
7163–7176. 
143. Leygue, E.; Dotzlaw, H.; Watson, P.H.; Murphy, L.C. Expression of the steroid receptor RNA 
activator in human breast tumors. Cancer Res. 1999, 59, 4190–4193. 
144. Hube, F.; Guo, J.M.; Chooniedass-Kothari, S.; Cooper, C.; Hamedani, M.K.; Dibrov, A.A.; 
Blanchard, A.A.A.; Wang, X.M.; Deng, G.; Myal, Y.; et al. Alternative splicing of the first 
intron of the steroid receptor RNA activator (SRA) participates in the generation of coding and 
noncoding RNA isoforms in breast cancer cell lines. DNA Cell Biol. 2006, 25, 418–428. 
145. Cooper, C.; Guo, J.M.; Yan, Y.; Chooniedass-Kothari, S.; Hube, F.; Hamedani, M.K.; Murphy, L.C.; 
Myal, Y.; Leygue, E. Increasing the relative expression of endogenous non-coding steroid 
receptor RNA activator (SRA) in human breast cancer cells using modified oligonucleotides. 
Nucleic Acids Res. 2009, 37, 4518–4531. 
146. Murphy, L.C.; Simon, S.L.R.; Parkes, A.; Leygue, E.; Dotzlaw, H.; Snell, L.; Troup, S.; 
Adeyinka, A.; Watson, P.H. Altered expression of estrogen receptor coregulators during human 
breast tumorigenesis. Cancer Res. 2000, 60, 6266–6271. 
147. Chooniedass-Kothari, S.; Hamedani, M.K.; Troup, S.; Hube, F.; Leygue, E. The steroid receptor 
RNA activator protein is expressed in breast tumor tissues. Int. J. Cancer 2006, 118, 1054–1059. 
148. Faust, T.; Frankel, A.; D’Orso, I. Transcription control by long non-coding RNAs. Transcription 
2012, 3, 78–86. 
149. Wassarman, D.A.; Steitz, J.A. Structural analyses of the 7SK ribonucleoprotein (RNP), the most 
abundant human small RNP of unknown function. Mol. Cell. Biol. 1991, 11, 3432–3445. 
150. Marz, M.; Donath, A.; Verstraete, N.; Nguyen, V.T.; Stadler, P.F.; Bensaude, O. Evolution of 
7SK RNA and its protein partners in metazoa. Mol. Biol. Evol. 2009, 26, 2821–2830. 
151. Krueger, B.J.; Jeronimo, C.; Roy, B.B.; Bouchard, A.; Barrandon, C.; Byers, S.A.; Searcey, C.E.; 
Cooper, J.J.; Bensaude, O.; Cohen, E.A.; et al. Larp7 is a stable component of the 7SK  
snRNP while P-Tefb, hexim1 and hnRNP A1 are reversibly associated. Nucleic Acids Res. 2008, 
36, 2219–2229. 
152. Markert, A.; Grimm, M.; Martinez, J.; Wiesner, J.; Meyerhans, A.; Meyuhas, O.; Sickmann, A.; 
Fischer, U. The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and 
affects transcription of cellular and viral polymerase II genes. EMBO Rep. 2008, 9, 569–575. 
153. Baek, D.; Villen, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P. The impact of micrornas 
on protein output. Nature 2008, 455, 64–71. 
154. Bartel, D.P. Micrornas: Target recognition and regulatory functions. Cell 2009, 136, 215–233. 
155. Ventura, A.; Jacks, T., MicroRNAs and cancer: Short RNAs go a long way. Cell 2009, 136,  
586–591. 
156. Lujambio, A.; Lowe, S.W. The microcosmos of cancer. Nature 2012, 482, 347–355. 
Cancers 2013, 5 488 
 
 
157. Ebert, M.S.; Sharp, P.A. Emerging roles for natural microRNA sponges. Curr. Biol. 2010, 20, 
R858–R861. 
158. Franco-Zorrilla, J.M.; Valli, A.; Todesco, M.; Mateos, I.; Puga, M.I.; Rubio-Somoza, I.; Leyva, A.; 
Weigel, D.; Garcia, J.A.; Paz-Ares, J. Target mimicry provides a new mechanism for regulation 
of microRNA activity. Nat. Genet. 2007, 39, 1033–1037. 
159. Cazalla, D.; Yario, T.; Steitz, J.A. Down-regulation of a host microRNA by a herpesvirus saimiri 
noncoding RNA. Science 2010, 328, 1563–1566. 
160. Panzitt, K.; Tschernatsch, M.M.; Guelly, C.; Moustafa, T.; Stradner, M.; Strohmaier, H.M.; 
Buck, C.R.; Denk, H.; Schroeder, R.; Trauner, M.; et al. Characterization of HULC, a novel gene 
with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 
2007, 132, 330–342. 
161. Almeida, M.I.; Reis, R.M.; Calin, G.A. Decoy activity through microRNAs: The therapeutic 
implications. Expert Opin. Biol. Ther. 2012, 12, 1153–1159. 
162. Sandberg, R.; Neilson, J.R.; Sarma, A.; Sharp, P.A.; Burge, C.B. Proliferating cells express 
mrnas with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008, 
320, 1643–1647. 
163. Katayama, S.; Tomaru, Y.; Kasukawa, T.; Waki, K.; Nakanishi, M.; Nakamura, M.; Nishida, H.; 
Yap, C.C.; Suzuki, M.; Kawai, J.; et al. Antisense transcription in the mammalian transcriptome. 
Science 2005, 309, 1564–1566. 
164. Carrieri, C.; Cimatti, L.; Biagioli, M.; Beugnet, A.; Zucchelli, S.; Fedele, S.; Pesce, E.; Ferrer, I.; 
Collavin, L.; Santoro, C.; et al. Long non-coding antisense RNA controls Uchl1 translation 
through an embedded SINEB2 repeat. Nature 2012, 491, 454–457. 
165. Matsui, K.; Nishizawa, M.; Ozaki, T.; Kimura, T.; Hashimoto, I.; Yamada, M.; Kaibori, M.; 
Kamiyama, Y.; Ito, S.; Okumura, T. Natural antisense transcript stabilizes inducible nitric oxide 
synthase messenger RNA in rat hepatocytes. Hepatology 2008, 47, 686–697. 
166. Yanagida, S.; Taniue, K.; Sugimasa, H.; Nasu, E.; Takeda, Y.; Kobayashi, M.; Yamamoto, T.; 
Okamoto, A.; Akiyama, T. ASBEL, an ANA/BTG3 antisense transcript required for 
tumorigenicity of ovarian carcinoma. Sci. Rep. 2013, 3, 1305. 
167. Yoon, J.H.; Abdelmohsen, K.; Gorospe, M. Posttranscriptional gene regulation by long 
noncoding RNA. J. Mol. Biol. 2012, doi:10.1016/j.jmb.2012.11.024. 
168. Faghihi, M.A.; Wahlestedt, C. Regulatory roles of natural antisense transcripts. Nat. Rev. Mol. 
Cell Biol. 2009, 10, 637–643. 
169. Kindler, S.; Wang, H.; Richter, D.; Tiedge, H. RNA transport and local control of translation. 
Annu. Rev. Cell Dev. Biol. 2005, 21, 223–245. 
170. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. P53 mutations in human cancers. 
Science 1991, 253, 49–53. 
171. Soussi, T.; Wiman, K.G. Shaping genetic alterations in human cancer: The p53 mutation 
paradigm. Cancer Cell 2007, 12, 303–312. 
172. Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 
2009, 9, 749–758. 
173. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. Cell 2009, 137, 
413–431. 
Cancers 2013, 5 489 
 
 
174. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. 
Nat. Rev. Mol. Cell Biol. 2008, 9, 402–412. 
175. Kubbutat, M.H.G.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by MDM2. Nature 
1997, 387, 299–303. 
176. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. MDM2 promotes the rapid degradation of p53. Nature 
1997, 387, 296–299. 
177. Harris, S.L.; Levine, A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 
2005, 24, 2899–2908. 
178. Gajjar, M.; Candeias, M.M.; Malbert-Colas, L.; Mazars, A.; Fujita, J.; Olivares-Illana, V.; 
Fahraeus, R. The p53 mRNA-MDM2 interaction controls MDM2 nuclear trafficking and is 
required for p53 activation following DNA damage. Cancer Cell 2012, 21, 25–35. 
179. Rastinejad, F.; Blau, H.M. Genetic complementation reveals a novel regulatory role for  
3' untranslated regions in growth and differentiation. Cell 1993, 72, 903–917. 
180. Khalil, A.M.; Guttman, M.; Huarte, M.; Garber, M.; Raj, A.; Morales, D.R.; Thomas, K.;  
Presser, A.; Bernstein, B.E.; van Oudenaarden, A.; et al. Many human large intergenic noncoding 
rnas associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. 
Acad. Sci. USA 2009, 106, 11667–11672. 
181. Bertani, S.; Sauer, S.; Bolotin, E.; Sauer, F. The noncoding RNA mistral activates Hoxa6 and 
Hoxa7 expression and stem cell differentiation by recruiting MLL1 to chromatin. Mol. Cell 2011, 
43, 1040–1046. 
182. Zhao, J.; Sun, B.K.; Erwin, J.A.; Song, J.J.; Lee, J.T. Polycomb proteins targeted by a short 
repeat RNA to the mouse x chromosome. Science 2008, 322, 750–756. 
183. Karapetyan, A.R.; Kuiper, R.A.; Coolen, M.W. Department of Human Genetics, Nijmegen 
Centre for Molecular Life Sciences (NCMLS), Radboud University Nijmegen Medical Centre, 
P.O. Box 9101, Nijmegen 6500 HB, The Netherlands. Unpublished work, 2013. 
184. Hamamoto, R.; Furukawa, Y.; Morita, M.; Iimura, Y.; Silva, F.P.; Li, M.; Yagyu, R.;  
Nakamura, Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of 
cancer cells. Nat. Cell Biol. 2004, 6, 731–740. 
185. Hamamoto, R.; Silva, F.P.; Tsuge, M.; Nishidate, T.; Katagiri, T.; Nakamura, Y.; Furukawa, Y. 
Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006, 
97, 113–118. 
186. St. Laurent, G.; Shtokalo, D.; Tackett, M.R.; Yang, Z.; Eremina, T.; Wahlestedt, C.;  
Urcuqui-Inchima, S.; Seilheimer, B.; McCaffrey, T.A.; Kapranov, P. Intronic RNAs constitute 
the major fraction of the non-coding RNA in mammalian cells. BMC Genomics 2012, 13, 504. 
187. Kanhere, A.; Viiri, K.; Araujo, C.C.; Rasaiyaah, J.; Bouwman, R.D.; Whyte, W.A.; Pereira, C.F.; 
Brookes, E.; Walker, K.; Bell, G.W.; et al. Short RNAs are transcribed from repressed polycomb 
target genes and interact with polycomb repressive complex-2. Mol. Cell 2010, 38, 675–688. 
188. Baltz, A.G.; Munschauer, M.; Schwanhausser, B.; Vasile, A.; Murakawa, Y.; Schueler, M.; 
Youngs, N.; Penfold-Brown, D.; Drew, K.; Milek, M.; et al. The mRNA-bound proteome and its 
global occupancy profile on protein-coding transcripts. Mol. Cell 2012, 46, 674–690. 
  
Cancers 2013, 5 490 
 
 
189. Castello, A.; Fischer, B.; Eichelbaum, K.; Horos, R.; Beckmann, B.M.; Strein, C.; Davey, N.E.; 
Humphreys, D.T.; Preiss, T.; Steinmetz, L.M.; et al. Insights into RNA biology from an atlas of 
mammalian mRNA-binding proteins. Cell 2012, 149, 1393–1406. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
